Tokyo Tape
Sign in
← Sapporo Clinical Laboratory

Quarterly report · Q3

9776.TEDINET S100Q4U9
Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥15.3bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥19.1bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥14.3bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥817m2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥1.1bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥972m2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥1.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.1bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥891m2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥1.0bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥493m2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.0bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥662m2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥578m2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥660m2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥16.9bnat 2022-12-31Cons.Assets
Total assets¥16.1bnat 2022-03-31Cons.Assets
Total assets¥15.5bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥6.1bnat 2022-12-31Cons.Liabilities
Total liabilities¥5.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥10.8bnat 2022-12-31Cons.Net assets
Net assets / equity¥10.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥10.0bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥4.1bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥3.0bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥147.852022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥70.532022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥306.162021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥193.962021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥59.832021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio62.2%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio63.2%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-12-31¥75m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-12-31¥73m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-12-31¥3m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-12-31¥49m
jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥6.4bn
jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥6.4bn
jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥532m
jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥8.0bn
jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥8.0bn
jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥601m
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥1.2bn
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥726m
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥495m
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentsegment profit2022-04-01 → 2022-12-31−¥8m
—segment totalrevenue2022-04-01 → 2022-12-31¥15.7bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥15.2bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥495m
—segment totalsegment profit2022-04-01 → 2022-12-31¥1.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥15.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥15.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥498m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥1.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-12-31¥80m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-12-31¥79m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-12-31¥723,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-12-31¥55m
jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥5.5bn
jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥5.5bn
jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥741m
jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥7.9bn
jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥7.9bn
jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥642m
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥1.7bn
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥724m
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥994m
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥12m
—segment totalrevenue2021-04-01 → 2021-12-31¥15.2bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥14.2bn
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥994m
—segment totalsegment profit2021-04-01 → 2021-12-31¥1.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥15.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥14.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥995m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥1.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 387
ItemContextValueUnit
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember724378000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember14206399000JPY
Revenues from external customersPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember79388000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember14285788000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E04950-000ClinicalTestingBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember994096000JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember994096000JPY
Transactions with other segmentsPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember723000JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember994819000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E04950-000ClinicalTestingBusinessReportableSegmentsMember5537336000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember7944685000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember1718474000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember15200496000JPY
Net salesPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember80111000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember15280607000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E04950-000ClinicalTestingBusinessReportableSegmentsMember741257000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember642074000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember11575000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember1394908000JPY
Operating incomePrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember54549000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember1449458000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E04950-000ClinicalTestingBusinessReportableSegmentsMember6411270000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember8039474000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember726418000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember15177162000JPY
Revenues from external customersCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember72942000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember15250105000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E04950-000ClinicalTestingBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember495312000JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember495312000JPY
Transactions with other segmentsCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember2556000JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember497868000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E04950-000ClinicalTestingBusinessReportableSegmentsMember6411270000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember8039474000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember1221730000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember15672474000JPY
Net salesCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember75498000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember15747973000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E04950-000ClinicalTestingBusinessReportableSegmentsMember532200000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember600512000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember-7718000JPY
Operating incomeCurrentYTDDuration_ReportableSegmentsMember1124994000JPY
Operating incomeCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember49123000JPY
Operating incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember1174118000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)北海道財務局長
Filing date cover pageFilingDateInstant2023-02-13

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass